Stock Research: Cochlear

Peer-based, data-driven stock research by Obermatt enables quick and easy due diligence for your stock investing.

What's New

Recent improvements to enhance your investment research experience

360° View free for everyone

Our most comprehensive analysis—the 360° View—is now free for everyone. To maintain our research quality, other ranks are now part of our new subscription plans.

3 new subscription models

Plans for every investor - from stock ideas to in-depth analysis.

Similar Stocks

Four stock alternatives to the stock you're searching.

Cochlear

ASX:COH AU000000COH5
31
  • Value
    43
  • Growth
    67
  • Safety
    Safety
    10
  • Combined
    27
  • Sentiment
    65
  • 360° View
    360° View
    31
Unlock
Which ranks are driving this 360° View?
Subscribe to View
Company Description

Cochlear Limited provides implantable hearing solutions. The company operates in the medical devices industry, specifically in hearing implants and related services. They operate globally, with a focus on providing solutions for hearing loss. In the last fiscal year, the company had a market cap of $12,783 million, profits of $1,130 million, and revenue of $1,490 million with 5000 employees.

more
Analysis

ANALYSIS: With an Obermatt 360° View of 31 (better than 31% compared with alternatives), overall professional sentiment and financial characteristics for the stock Cochlear are below the industry average. The 360° View is based on consolidating four consolidated indicators, with half of the metrics below and half above average for Cochlear. The consolidated Growth Rank has a good rank of 67, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth as well as stock returns. This means that growth is higher than for 67% of competitors in the same industry. The consolidated Sentiment Rank also has a good rank of 65, which means that professional investors are more optimistic about the stock than for 65% of alternative investment opportunities. But the consolidated Value Rank has a less desirable rank of 10, which means that the share price of Cochlear is on the higher side compared with typical size in indicators such as revenues, profits, and invested capital. This means the stock price is higher than for 90% of alternative stocks in the same industry. Finally, the consolidated Safety Rank has a riskier rank of 43, which means that the company has a financing structure that is riskier than those of 57% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. ...read more

more
Index
ASX 100
ASX 200
ASX 300
ASX 50
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 21-Aug-2025.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
10 13 10 23
Growth
67 21 89 45
Safety
Safety
43 41 50 55
Sentiment
65 14 39 27
360° View
360° View
31 1 41 19
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Analyst Opinions
21 23 3 19
Opinions Change
48 10 55 44
Pro Holdings
n/a 25 66 37
Market Pulse
83 77 76 71
Sentiment
65 14 39 27
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
10 13 10 23
Growth
67 21 89 45
Safety Safety
43 41 50 55
Combined
27 4 52 29
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Price vs. Sales (P/S)
12 9 12 22
Price vs. Earnings (P/E)
5 7 5 19
Price vs. Book (P/B)
3 5 5 13
Dividend Yield
37 47 46 46
Value
10 13 10 23
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Revenue Growth
69 65 59 54
Profit Growth
65 44 72 50
Capital Growth
56 18 47 33
Stock Returns
51 13 91 57
Growth
67 21 89 45
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Leverage
63 56 61 58
Refinancing
20 18 23 37
Liquidity
58 57 56 50
Safety Safety
43 41 50 55

Similar Stocks

Discover high‑ranked alternatives to Cochlear and broaden your portfolio horizons.

Nipro

TSE:8086
Country: Japan
Industry: Health Care Supplies
Size: Large
Full Stock Analysis

Asahi Intecc

TSE:7747
Country: Japan
Industry: Health Care Supplies
Size: Medium
Full Stock Analysis

M3

TSE:2413
Country: Japan
Industry: Health Care Technology
Size: Medium
Full Stock Analysis

Suncorp

ASX:SUN
Country: Australia
Industry: Property & Casualty Insurance
Size: Medium
Full Stock Analysis

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.